The Insulin That Kids Don't Have to Stab Themselves With
Inhaled insulin flopped spectacularly with adults. Now MannKind's Afrezza just became the first needle-free mealtime insulin approved for kids, targeting a population where needle fear isn't just annoying — it's clinically dangerous.
A Billion-Dollar Failure Gets a Second Life
Imagine telling a six-year-old they need to stick a needle into their body before every meal, every single day, for the rest of their life. Now imagine telling them they can just breathe in their medicine instead.
That's the promise the FDA just made real. MannKind's Afrezza, an inhaled mealtime insulin delivered as a powder through a small cartridge, just won approval for children and adolescents aged six and older with type 1 or type 2 diabetes. It's the first needle-free inhaled insulin ever cleared for pediatric patients.
What makes this remarkable isn't just the approval itself. It's where this product came from. Inhaled insulin has been one of biotech's most infamous punchlines for nearly two decades. And somehow, against all commercial logic, it just found new life in the last population anyone expected.
The Graveyard Before the Garden
To understand why this matters, you need to know how badly inhaled insulin has flopped before.
Pfizer launched Exubera, the first inhaled insulin, in 2006 with blockbuster dreams. The company once projected billions in annual sales. Reality delivered $12 million over nine months in 2007 before Pfizer pulled the plug entirely. The inhaler was bulky, the cost was high, and doctors simply didn't see enough upside over a standard needle.
MannKind tried again with Afrezza, winning FDA approval for adults in 2014. Sanofi signed on to market the drug. First-quarter 2015 sales? $1.1 million. By the end of that year, Afrezza had managed roughly $12.6 million in total revenue. Sanofi bailed in January 2016.
For years, the conventional wisdom was clear: inhaled insulin solves a problem patients don't care enough about. Needles are annoying, sure. But they work. They're cheap. They're familiar. Asking someone to switch to a new device with a restricted label, lung-function monitoring requirements, and a higher price tag was a tough sell.
So why would the pediatric market be any different?
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Because Kids Aren't Just Small Adults
About 27% of children with type 1 diabetes have significant needle anxiety, according to validated screening tools. In some studies, roughly a third of youth report strong negative feelings about their insulin injections. This isn't garden-variety discomfort. It's the kind of fear that makes kids skip doses, avoid blood sugar checks, and fight their parents at the dinner table.
And the consequences are measurable. Research shows that pediatric patients with higher needle-fear scores tend to have worse blood sugar control and less frequent monitoring. For adults, needle aversion is a minor inconvenience. For a seven-year-old with type 1 diabetes, it can be a clinical crisis.
Insulin pumps help reduce the frequency of needle sticks, but they still require a cannula insertion every few days (which plenty of kids rate as painful and scary). CGMs cut down on fingersticks, but sensor insertion involves, yes, another needle. Every existing solution reduces needle exposure without eliminating it.
Afrezza is the first option that takes the needle out of the mealtime equation entirely.
The Data: Good Enough to Clear the Bar
MannKind's INHALE-1 trial randomized 230 kids (ages 4 to 17) with type 1 diabetes to either Afrezza plus basal insulin or standard rapid-acting injections plus basal insulin. The study ran for 26 weeks with a 26-week safety extension.
The primary goal was non-inferiority, meaning Afrezza needed to show it controlled blood sugar about as well as injected insulin. In the full analysis, Afrezza narrowly missed the prespecified margin by a hair (0.435% vs. the 0.4% threshold). But that miss was traced largely to one highly non-adherent patient in the Afrezza group. Remove that single outlier, and the difference drops to 0.370%, comfortably inside the non-inferiority window.
Michael Haller, MD, summarized it simply: "The primary outcome essentially showed non-inferiority of inhaled insulin compared to rapid-acting injected insulin."
Time in range (the percentage of the day a patient's blood sugar stays between 70 and 180 mg/dL) was comparable between groups. Hypoglycemia rates showed no significant differences. And critically, lung function didn't budge. Kids on Afrezza maintained essentially the same FEV1 (a measure of how well the lungs work) as those on injections over six months.
The safety profile matched what doctors have seen in adults: some cough, some throat irritation, and a boxed warning against use in patients with chronic lung disease like asthma. That last point is worth flagging; asthma is common in kids, so screening with lung-function tests before starting Afrezza will be a real-world consideration.
Wall Street Already Priced This In (Mostly)
MannKind's stock tells a complicated story. The company now carries a consensus "Buy" rating from analysts, with an average 12-month price target hovering around $9. But the range is enormous: from $4.75 (RBC) to $15 (Oppenheimer). That spread tells you there's genuine disagreement about how this plays out.
Most sell-side models already baked in the pediatric approval. Management has guided to a $450 million revenue run-rate for 2026, with the pediatric Afrezza launch as a key ingredient alongside Tyvaso DPI royalties and their newer product, Furoscix. MannKind's own management estimates peg the pediatric segment alone as a $300 to $500 million annual opportunity, though full penetration likely won't arrive until 2027 or beyond.
The bull case writes itself: there are roughly 300,000 youth with type 1 diabetes in the U.S. today, and incidence is climbing about 2% per year. And the ADA's Standards of Care now formally recognize inhaled Afrezza as an alternative mealtime insulin option alongside injections and pumps.
The bear case is equally straightforward. Afrezza flopped with adults for real reasons: cost, restricted labeling, the need for lung monitoring, and physician inertia. Pediatric endocrinologists may be just as conservative. Getting onto formularies and convincing insurance companies to cover a premium product for kids won't happen overnight.
The Bigger Picture
What's fascinating here is the strategic inversion. Inhaled insulin failed in adults partly because the needle problem wasn't painful enough (figuratively) to drive switching. For kids, the needle problem is genuinely clinical. Fear leads to missed doses, which leads to poor control, which leads to long-term complications.
Afrezza doesn't need to be better than injections. It just needs to be roughly as good while removing the thing that makes a six-year-old cry at breakfast. The INHALE-1 data suggest it clears that bar.
Whether MannKind can turn that clinical logic into commercial success is the trillion-dollar (well, $450 million) question. The company has been here before: strong science, clear patient need, disappointing sales. But this time the patient population is different, the unmet need is sharper, and the company isn't relying on a partner who might walk away.
Sometimes the best market for a product isn't the one you designed it for. It's the one where the pain is loudest.
5 min read
The Pill That Crosses the Brain's Toughest Bouncer
Sanofi's venglustat just scored FDA Priority Review for Gaucher disease type 3, and it could become the first approved therapy to actually cross the blood-brain barrier and treat the devastating neurological symptoms. The decision date is set for November 25, 2026.
